Orthofix International (OFIX) Stock Forecast & Price Target

Orthofix Medical Inc. has demonstrated robust growth in its Global Spine segment, reporting a 10% increase in revenue, driven by significant advancements in various product categories, including a 24% growth in lateral spinal fixation and an 18% increase in minimally invasive lumbar procedures. The U.S. limb reconstruction sector also showed healthy performance with an 8% revenue growth, indicating strong demand for their orthopedic solutions. Furthermore, Orthofix’s management anticipates ongoing growth in its bone growth therapies business, supported by successful cross-selling initiatives and an expected market growth rate of 2% to 3%.

Orthofix Medical's financial outlook has been negatively impacted by lowered guidance for fiscal years 2026 and 2027, which fell short of previous management expectations, alongside a delayed target for adjusted EBITDA margins now set for 2028. Although the company reported revenue of $219.9 million exceeding estimates, the performance in its Global Spine segment, particularly spinal implants and biologics, failed to meet projections, indicating underlying weaknesses. Furthermore, the increased SG&A expenses, which reached 72.0% of revenue compared to expectations of 66.7%, suggest operational inefficiencies that could hinder profitability moving forward.